Hmmm. So E&P are now valuing Neuren at $17 when th relatively conservative and simple PE calculations that multiple people have posted here based upon fully disclosed data show $20 to $70 on NA Retts alone. I'd love to see how on earth they can get such a low number out of their valuation model. They must be valuing the rest of Neurens potential at minus $20 to minus $50 a share or something.As I alluded to previously, E&P appear to be following the analyst rule of thumb to never value a company at more than twice its current share price, no matter what the numbers say.
Can someone explain to me how an analyst can use the publicly available information to calculate a valuation of just $17 a share? I'm mystified.
Share Price Target IF approved., page-46
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |